Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Graff

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Oncotarget|October 27, 2017
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancerJennifer Podolak, Kristi Eilers, Timothy Newby, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Neurology|April 28, 2012
Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memoryS Barral, T Bird, A Goate, et al.
Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.
Urologic Oncology|November 10, 2019
Real-world practice patterns in veterans with metastatic castration-resistant prostate cancerAhmad S Halwani, Kelli M Rasmussen, Vikas Patil, et al.
Neuroscience Letters|May 4, 2000
No association between TAU haplotype and Alzheimer's disease in population or clinic based series or in familial diseaseM Baker, D Graff-Radford, F Wavrant DeVrièze, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Human Molecular Genetics|November 5, 1997
A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43)C B Eckman, N D Mehta, R Crook, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
Nature|March 24, 2022
Androgen receptor activity in T cells limits checkpoint blockade efficacyXiangnan Guan, Fanny Polesso, Chaojie Wang, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Oncotarget|October 27, 2017
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancerJennifer Podolak, Kristi Eilers, Timothy Newby, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Neurology|April 28, 2012
Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memoryS Barral, T Bird, A Goate, et al.
Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.
Urologic Oncology|November 10, 2019
Real-world practice patterns in veterans with metastatic castration-resistant prostate cancerAhmad S Halwani, Kelli M Rasmussen, Vikas Patil, et al.
Neuroscience Letters|May 4, 2000
No association between TAU haplotype and Alzheimer's disease in population or clinic based series or in familial diseaseM Baker, D Graff-Radford, F Wavrant DeVrièze, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Human Molecular Genetics|November 5, 1997
A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43)C B Eckman, N D Mehta, R Crook, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
Nature|March 24, 2022
Androgen receptor activity in T cells limits checkpoint blockade efficacyXiangnan Guan, Fanny Polesso, Chaojie Wang, et al.
Pageof 12